vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, October 5th.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
VTVT has been the topic of a number of other research reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 target price on shares of vTv Therapeutics in a research report on Friday, August 4th. HC Wainwright set a $13.00 target price on shares of vTv Therapeutics and gave the company a “buy” rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $14.50.
Shares of vTv Therapeutics (NASDAQ:VTVT) traded down 0.55% during trading on Thursday, hitting $7.20. 4,384 shares of the company traded hands. The company’s market capitalization is $69.79 million. The company has a 50 day moving average price of $6.09 and a 200 day moving average price of $6.09. vTv Therapeutics has a 52 week low of $3.57 and a 52 week high of $8.09.
vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.19 million. On average, analysts expect that vTv Therapeutics will post ($1.06) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/markets/vtv-therapeutics-inc-vtvt-cut-to-hold-at-zacks-investment-research/1699166.html.
In other news, major shareholder Ronald O. Perelman bought 10,000 shares of vTv Therapeutics stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average price of $4.97 per share, with a total value of $49,700.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ronald O. Perelman bought 50,000 shares of vTv Therapeutics stock in a transaction that occurred on Tuesday, August 15th. The stock was purchased at an average cost of $4.72 per share, for a total transaction of $236,000.00. The disclosure for this purchase can be found here. Insiders have bought 165,000 shares of company stock worth $728,150 in the last three months. Corporate insiders own 0.80% of the company’s stock.
Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its holdings in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 1,305 shares in the last quarter. Renaissance Technologies LLC raised its holdings in vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 2,900 shares in the last quarter. State Street Corp raised its holdings in vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in vTv Therapeutics by 62.7% in the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after acquiring an additional 101,850 shares in the last quarter. 11.05% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with our FREE daily email newsletter.